89ZR-BEVACIZUMAB ( DrugBank: Bevacizumab, 89ZR-BEVACIZUMAB )


1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis


Clinical trials : 133 Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000156-35-NL
(EUCTR)
18/03/202103/03/202089Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. - 89Zr-Bevacizumab PET/CT imaging in NF2 patients Neurofibromatosis type 2;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: 89Zr-bevacizumab
INN or Proposed INN: Unknown
Other descriptive name: BEVACIZUMAB ZIRCONIUM ZR-89
Leiden University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
15Phase 2Netherlands